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Abstract
Background: In our previous study, it was well defined that IGFBP7 was an important tumor suppressor gene in 
colorectal cancer (CRC). We aimed to uncover the downstream molecules responsible for IGFBP7's behaviour in this 
study.
Methods: Differentially expressed protein profiles between PcDNA3.1(IGFBP7)-transfected RKO cells and the empty 
vector transfected controls were generated by two-dimensional gel electrophoresis (2-DE) and mass spectrometry 
(MS) identification. The selected differentially expressed protein induced by IGFBP7 was confirmed by western blot and 
ELISA. The biological behaviour of the protein was explored by cell growth assay and colony formation assay.
Results: Six unique proteins were found differentially expressed in PcDNA3.1(IGFBP7)-transfected RKO cells, including 
albumin (ALB), 60 kDa heat shock protein(HSP60), Actin cytoplasmic 1 or 2, pyruvate kinase muscle 2(PKM2), beta 
subunit of phenylalanyl-tRNA synthetase(FARSB) and hypothetical protein. The downregulation of HSP60 by IGFBP7 
was confirmed by western blot and ELISA. Recombinant human HSP60 protein could increase the proliferation rate 
and the colony formation ability of PcDNA3.1(IGFBP7)-RKO cells.
Conclusion: HSP60 was an important downstream molecule of IGFBP7. The downregulation of HSP60 induced by 
IGFBP7 may be, at least in part, responsible for IGFBP7's tumor suppressive biological behaviour in CRC.
Introduction
Colorectal cancer (CRC) is the third most common
malignancy in the world. Colorectal carcinogenesis has
been conceptualized as a multi-step, multi-mechanism
process, consisting of an initiation, promotion and pro-
gression phase, which developed via a progressive accu-
mulation of genetic mutations. Understanding the
neoplastic progression of CRC at the cellular and molecu-
lar levels can facilitate diagnosis and treatment of cancer.
Our lab has been devoted to research on the molecular
mechanism of CRC for decades of years. In 1999, we sep-
arated the insulin-like growth factor binding protein 7
(IGFBP7) cDNA fragments from colonic adenocarci-
noma and normal mucosa cDNA subtraction libraries by
suppressive subtractive hybridization (SSH)[1]. IGFBP7
was cloned as a senescence-associated gene from human
mammary epithelial cells[2], also named as insulin-like
growth factor binding protein-related protein 1 (IGFBP-
rP1)[3], meningioma associated cDNA 25 (MAC25)[2,4],
tumor-derived adhesion factor(TAF)[5], and prostacylin-
stimulating factor(PSF)[6]. After the separation of
IGFBP7, we then devoted to elaborate the biological role
of the protein in CRC. Our group presented evidence that
reintroduction of IGFBP7  suppressed the proliferation,
decreased the colony formation ability, and induced
apoptosis in two colorectal carcinoma cell lines RKO and
SW620[7]. IGFBP7 protein could induce G1 cell cycle
arrest in RKO and CW2 cells. A senescence-like pheno-
type was induced by IGFBP7 in these colon cancer
cells[8]. We also found that overexpression of IGFBP7 in
CRC tissue correlated with favourable prognosis, the
higher IGFBP7 expressed the longer will the patient sur-
vive[7,9]. All these findings strongly supported that
IGFBP7 played a potential tumor suppressor role against
colorectal carcinogenesis. In consistent with our findings,
the tumor suppressor roles of IGFBP7 in cervical can-
cer[10], osteosarcoma[10,11], prostate cancer[12,13], and
breast cancer[14] were discovered by other laboratories.
The important function of IGFBP7 protein in CRC has
elicited the need to further investigate the underlying
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mechanism. Proteomics represents a powerful approach
to analyze alterations in protein expression in complex
biological system. This approach has been used success-
fully in our lab to identify differentially expressed pro-
teins between tissue of colorectal carcinoma, colon
adenoma, and the normal mucosa, which have potential
clinical interest [15,16]. In this study, our main goal was
to identify proteins associated with IGFBP7 expression
using the proteomics-based approach and further clarify
the protein's biological role. These findings will contrib-
ute to our understanding for the molecular mechanism
responsible for IGFBP7's tumor suppressive function in
CRC.
Methods
Reagents
Dulbecco's Modified Eagle's Medium(DMEM)was pur-
chased from GIBCO Laboratories (Grand Island, NY,
USA). Fetal bovine serum (FBS) was purchased from
HyClone Laboratories (Logan, UT, USA). Polyfect trans-
fection reagent was purchased from QIAGEN (Hilden,
Germany). G418 was purchased from Merck (Darmstadt,
Germany). Immobiline Dry-Strips (17 cm, pH 3-10 NL),
immobilized pH gradient (IPG) buffer, Dry-Strip cover
fluid, urea, thiourea, ammonium bicarbonate and sodium
dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-
PAGE) standards were purchased from BioRad (Hercules,
CA, USA). Dithiothreitol (DTT), trifluoroacetic acid
(TFA), acrylamide, cellulose acetate nitrate (ACN), glyc-
erol, glycine, iodoacetamide3-((3-cholamidopropyl)dime-
thylammonio)-1-propanesulfonic acid (CHAPS), bis-
hydroxymethyl-oxazoline (Bis), tetramethylethylenedi-
amine (TEMED), sodium dodecyl sulfate (SDS), tris-
hydroxymethyl-aminomethane (Tris base), dimethylsul-
foxide (DMSO), bovine serum albumin (BSA) and Coo-
massie brilliant blue (CBB R-250) were obtained from
Sigma Chemical (St. Louis, MO, USA). Cell lysis buffer,
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibody, 60 kDa heat shock protein (HSP60) antibody,
and horseradish peroxidase-linked second antibody were
purchased from cell signaling Technology (Danvers, MA,
USA). Recombinant human HSP60 protein and HSP60
ELISA kit were purchased from StressGen Biotechnolo-
gies (Victoria, British Columbia, Canada).
Cell culture and protein extraction
Human colorectal carcinoma RKO cell lines were derived
from the American Type Culture Collection (ATCC),
maintained in DMEM supplemented with 10% FBS in a
37°C/5% CO2 atmosphere. RKO cells were transfected
with either PcDNA3.1(IGFBP7) or an empty plasmid vec-
tor PcDNA3.1. Stable PcDNA3.1(IGFBP7)-RKO transfec-
tants and PcDNA3.1-RKO transfectants were established
as previously described[7]. For the proteomics analysis,
the two groups of cells were cultured in the same condi-
tions, maintained at 80% confluence and in exponential
growth phase, harvested at the same time. Cells were
washed with phosphate buffered saline (PBS) 3 times, sol-
ubilized in cell lysis buffer on ice for 30 min, followed by
centrifugation at 100,000 g for 60 min at 4°C. The protein
concentration was determined according to the method
of Bradford. Samples were stored at -80°C.
Two-dimensional electrophoresis (2-DE)
Briefly, linear gradient 24-cm (pH 5-8) readystrip (Bio-
Rad) was rehydrated overnight at 17°C with 300 μg of
protein samples in 500 μl of rehydration buffer (7 M urea,
2 M thiourea, 4% CHAPS, 65 mM DTT, and 0.2% Bio-
Lyte). Isoelectric focusing (IEF) was performed by using
PROTEAN IEF Cell (Bio-Rad). After IEF, the IPG strip
was immediately equilibrated for 15 mins in equilibration
buffer I (6 M urea, 2% SDS, 0.375 M Tris-HCl pH 8.8, 20%
glycerol, and 2% DTT) and then for 15 mins in equilibra-
tion buffer II (6 M urea, 2% SDS, 0.375 M Tris-HCl pH
8.8, 20% glycerol, and 2.5% iodoaceta-mide). SDS-PAGE
was carried out on 12% SDS-polyacrylamide gels (25 cm
× 20.5 cm × 1.0 mm) by using the PROTEAN Plus
Dodeca Cell (Bio-Rad) at a constant voltage of 200 V at
20°C. After electrophoresis, the gels were stained by using
the Silver Stain Plus Kit (Bio-Rad). The above processes
were performed in triplicate for each sample.
Image Analysis
The silver-stained 2-DE gels were scanned on a GS-800
Calibrated Imaging Densitometer (Bio-Rad) at a resolu-
tion of 300 dots per inch (dpi). Spot detection, quantifica-
tion, and the analyses of 2-D protein patterns were done
with the PDQuest software (version 7.1, BioRad). Then
the report of quantitative differences between two gel
images was generated. The gray values of the differen-
tially expressed protein candidates were statistically ana-
lyzed by the nonparametric Wilcoxon test. Protein spots
that showed more than 3-fold differential expression
reproducible in the three gels were taken as differentially
expressed candidates and selected.
Spot Cutting and In-Gel Digestion
Differentially expressed protein spots identified as
described in the preceding text were excised from gels by
Proteomeworks Spot Cutter (Bio-Rad), destained for 20
mins in 30 mM potassium ferricyanide/100 mM sodium
thiosulfate (1:1 [v/v]), and washed in Milli-Q water until
the gels shrank and were bleached. The gel pieces were
incubated in 0.2 M NH4HCO3 for 20 mins and dried by
lyophilization. To each gel piece, 20 μl of 20 μg/ml trypsin
(proteomics grade, Sigma, St. Louis, MO) was added and
incubated at 37°C overnight. The peptides were extracted
three times with 50% ACN and 0.1% TFA and dried in a
vacuum centrifuge.Ruan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:41
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Matrix-assisted laser desorption ionization/time-of-flight 
mass spectroscopy (MALDI-TOF-MS) analysis and database 
search
Samples were analyzed by a Voyager-DE STR MALDI-
TOF mass spectrometer (Applied Biosystems, Foster
City, CA) with delayed extraction in which α-cyano-4-
hydroxycinnamic acid was exploited as the matrix (in
50% ACN in 0.05% MS). The total 2 μl solution was
applied onto a target disk and allowed to air dry. Mass-to-
charge ratios were measured in a reflector/delayed
extraction mode with an accelerating voltage of 20 kV, a
grid voltage of 63%-65%, positive polarity, and a delay
time of 200 nanoseconds. Laser shots at 300 per spec-
trum were used to acquire the spectra with a range from
800 to 4000 Daltons. Trypsin autolysis products were
used for internal mass calibration. Database searching
was performed by using Mascot software http://
www.matrixscience.com. The search parameters were the
nrNCBI database, human, 10-150 kDa, trypsin (1 missed
enzymatic cleavage), and 100-ppm mass tolerance. The
best match was the one with the highest score, and a sig-
nificant match was typically a score of the order of 70 (P <
0.05) [16,17].
Western blot
Cell lysates (50 μg) were loaded onto 12% SDS-polyacryl-
amide gels, transferred onto nitrocellulose membranes,
and subjected to western blot analysis[7]. The transferred
membranes were incubated overnight at 4°C with rabbit
polyclonal antibodies against HSP60 at 1:1000 dilutions.
The membranes then were washed three times in Tris
Buffered Saline with Tween (TBST). Bands were detected
using a horseradish peroxidase-linked second antibody
and enhanced chemiluminescence reagents, according to
the manufacturer's protocol.
Enzyme-linked immunosorbent assay (ELISA)
Equivalent numbers 1 × 106 of PcDNA3.1(IGFBP7)-RKO
transfectants and PcDNA3.1-RKO transfectants (control)
were plated in 6-well plates. After attachment, the media
were then changed to 1.5 ml of serum-free media and
allowed to incubate on the cells for additional 24 h. The
cell supernatants were then collected, centrifuged to dis-
card cellular debris, and analyzed using HSP60 ELISA kit
as recommended by the manufacturer.
Cell proliferation assay
Cell proliferation was measured using the cell counting
kit-8 (CCK-8, Dojindo Laboratories, Japan). In brief,
PcDNA3.1(IGFBP7)-RKO cells were plated in sextuple in
96-well microtitre plates at 3 × 103/well, cultured with
medium with or without recombinant HSP60 protein(1
μg/ml). T en μl of CCK8 was added to each well at the
time of harvest (12 h, 24 h, 36 h, 48 h, 60 h, 72 h). Two
hours after adding CCK8, cellular viability was deter-
mined by measuring the absorbance of the converted dye
at 450 nm.
Anchorage-independent growth assay
PcDNA3.1(IGFBP7)-RKO cells (500/well) were seeded
into 0.3% Bacto-agar (Sigma, St Louis, MO, USA) over a
0.6% agar bottom layer in triplicate in 6-well plates, with
or without 1 μg/ml HSP60. Plates were incubated in a
37°C/5% CO2, humid atmosphere for 3 weeks. Colonies
were counted using a dissecting microscope. The wells
were then analyzed for colony number and size. Colonies
>100 μm in diameter were counted under a dissecting
microscope. Three independent experiments were con-
ducted.
Statistical Analysis
All experiments were done in triplicate. Differences
between control and treated cells were assessed using
one-way ANOVA and a significance level of P < 0.05 was
required.
Results
Comparative proteomics analysis
The silver-stained 2D-PAGE profile of the
PcDNA3.1(IGFBP7)-RKO transfectants and the
PcDNA3.1-RKO -transfectants revealed approximate
1100 staining spots (1171 ± 109 vs 1120 ± 80), respec-
tively. Using a 3-fold criterion for selecting, 12 protein
spots were visually detected as significantly differentially
expressed between the two groups. The representative
images, emphasizing the location of the 12 protein spots
on the gel were shown in Figure 1. Interestingly, of the 12
spots, only one spot was upregulated (spot 12) and the
other 11 spots were downregulated in the cell lysates of
PcDNA3.1(IGFBP7)-RKO transfectants.
MS based identification
The above 12 differentially expressed protein spots were
selected and submitted to MS based identification. As a
result, 10 spots were identified by MALDI-TOF MS, rep-
resenting 6 unique proteins, including albumin (ALB),
HSP60, Actin cytoplasmic 1 or 2, pyruvate kinase muscle
2(PKM2), beta subunit of phenylalanyl-tRNA syn-
thetase(FARSB) and hypothetical protein (Table 1). Two
protein spots (spot 11 and spot 12) could not be identi-
fied, possibly due to the lower amount of protein as
revealed by a retrospective analysis of the spot volumes.
Of the 6 proteins identified above, all were found
decreased in PcDNA3.1(IGFBP7)-RKO transfectants.
Confirmatory studies of downregulation of HSP60 by 
Western blot and ELISA
In particular, we focused on the protein spot 8 and 9. We
identified these two spots as the HSP60, with a molecularRuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:41
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weight of 61.055 kDa, and a pI value of 5.70. The spec-
trum figure of HSP60 was presented in Figure 2. Western
blot results using the cell lysates samples confirmed the
findings that the expression of HSP60 was significantly
lower in the cell lysates of PcDNA3.1(IGFBP7)-RKO
transfectants. A representative image was presented in
Figure 3A. The secretion of HSP60 was also compared
between the supernatants from PcDNA3.1(IGFBP7)-
RKO transfectants and controls using ELISA. Secretion
of HSP60 was also found to be downregulated by IGFBP7
(Figure 3B).
Recombinant HSP60 reversed the proliferation inhibition 
induced by IGFBP7
To clarify the biological effect of HSP60 downregulation
induced by IGFBP7 in RKO cells, we studied the function
of recombinant HSP60 on the proliferation of
PcDNA3.1(IGFBP7)-RKO cells. We found that addition
of HSP60 protein could promote the cell proliferation
rate of PcDNA3.1(IGFBP7)-RKO cells(Figure 4A). HSP60
could also increase the colony formation ability and the
colony size of the cells (Figure 4B, 4C).
Discussion
Here we describe a proteomics study of two human colon
cancer cell lines differing in the expression of IGFBP7,
which is an important tumor suppressor gene well
defined by our previous studies[7]. To our knowledge,
this is the first proteomic study on the alterations of
IGFBP7 protein expression profiles in colon cancer cells.
We were successful in identifying six IGFBP7-associated
downstream target proteins, including ALB, HSP60,
Actin cytoplasmic 1 or 2, PKM2, FARSB and hypothetical
protein. These differentially expressed proteins represent
candidate proteins that may be directly or indirectly regu-
lated by IGFBP7.
The comparation between the current findings at the
translation level and our previous studies identifying the
Figure 1 2D electrophoresis profiles of PcDNA3.1(IGFBP7)-RKO-transfectants and PcDNA3.1-RKO transfectants. A. 2D electrophoresis profiles 
of silver staining proteins of PcDNA3.1(IGFBP7)-RKO transfectants (BP7-RKO) and PcDNA3.1-RKO transfectants (control). 0.75 milligrams of protein were 
loaded onto linear IPG strips (pH 5-8) and isoelectric focusing was performed at 35 kV-h. The second dimensional run was performed on 12.5% Tris-
glycine-PAGE gels and the gels were stained with silver for image analysis. Protein spot discrepancies were arrowed and marked with number. B. 
Close-up image of differential expression of protein spots.Ruan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:41
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IGFBP7-induced genes at the transcriptional level
detected by Affymetrix chip platform(unpublished data)
resulted in some interesting points in agreement. The
proteomics finding indicated that actin was influenced by
IGFBP7. While the cDNA array studies also indicated
that the actin binding proteins were greatly influenced by
IGFBP7. These findings at both the transcriptional and
the translational level suggested that IGFBP7 may possi-
Figure 2 LC-MS spectrum obtained for spot 9. Peptide fragments were analyzed by LC-tandem MS and MALDI-TOF analysis of peak m/z was per-
formed. Major monoisotopic peaks of trypsin-digested peptides, detected by MALDI-TOF MS, are indicated on the spectrum. The sequence of HSP60 
protein was represented by single-letter code for amino acids on the top left corner of the image, where peptide matches between the sample and 
the HSP60 sequence are shown bold.
Table 1: Characteristics of proteins identified from PcDNA3.1(IGFBP7)-transfected RKO cells and controls
Spot Protein description Sequence coverage(%)* Swissprot ID Theoretical Mr/Pi**
1 Serum albumin 5.74% P02768 69367/6.42
2 Serum albumin 7.97% P02768 69367/6.42
3 Serum albumin 6.86% P02768 69367/6.42
4 pyruvate kinase, muscle 22.45% Q9UK31 6002/7.58
5 Phenylalanyl-tRNA synthetase beta chain 12.56% Q9NSD9 66130/6.39
6 Actin, cytoplasmic 1 or 2 33.33% P63261 41793/5.31
7 Actin, cytoplasmic 1 or 2 23.20% P63261 41793/5.31
8 60 kDa heat shock protein, mitochondrial 
precursor
2.96% P10809 61055/5.7
9 60 kDa heat shock protein, mitochondrial 
precursor
28.52% P10809 61055/5.7
10 Hypothetical protein 21.49% P04406 36053.05/8.57
* Sequence coverage was calculated by amino acid count **Calculated from the database entry without any processingRuan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:41
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bly be an actin-binding associated gene, which need our
further study to provide the direct evidence.
However, there is little overlap of identified genes
between our mRNA and protein data, consistent with the
d a t a  r e v i e w e d  b y  S a g y n a l i e v  a n d  t h e  c o l l e a g u e s  t h a t
among various gene expression studies only about 25% of
differentially expressed proteins were reflected by con-
comitant changes at the mRNA level in CRC [18]. This
may be due to two reasons. First, the lower dynamic
range of the 2D PAGE protocol allows less abundant pro-
teins to escape detection [19]. With only around 1100
protein spots visible, this approach allows the analysis of
only a fraction of the total number of proteins expressed
in the cell. Second, from the transcriptional profiles, we
found that IGFBP7 could influence the expression levels
of many secretary genes. However, many of them could
not be detected by the current proteomics approach in
the cell lysates samples. Secretome studies performed in
the supermedium of the cells will probably enlarge our
finding [20].
Among the differentially expressed proteins induced by
IGFBP7, HSP60 attracted our attention. Heat shock pro-
teins (HSPs) are a family of highly conserved proteins
induced by various kinds of stress, mostly localized in the
mitochondrial matrix, including HSP60, HSP90, HSP70
and small HSPs. They are with the principal function as
molecular chaperones results in the maintenance of sta-
bility and delivery of other peptide [21]. Recently, HSPs
are implicated in several important cellular processes,
including DNA replication, gene expression regulation,
signal transduction, differentiation, apoptosis, or immor-
talization[22]. Our data obtained from western blot using
the cell lysates confirmed the proteomics finding that
HSP60 was downregulated in PcDNA3.1(IGFBP7)-RKO
transfectants. Similar with the secretary character of
IGFBP7, in addition to the cytosolic locations, HSP60
also could be detected in the extracellular space and in
circulation[23,24]. Thus, we also analysed the secretion of
HSP60 in the supernatants of the cells using ELISA. Con-
sistent with the expression level in the cell lysates, it was
found that the IGFBP7 could also decrease the secretion
of HSP60 in RKO cells.
The role of HSP60 played in cancer has been investi-
gated by numerous studies. Strong patterns of increased
HSP60 immunostaining from normal tissues, through
cervical intraepithelial neoplasia grade (CIN)1, to CIN3
was found, in a manner similar to cyclin-dependent
kinase inhibitor 2A (CDKN 2A), a biomarker of onco-
genic human papillomaviruses (HPV) infections and
CIN3[25]. In breast cancer, HSP60 expression gradually
increased from normal through ductal carcinoma in situ
(DCIS) to invasive tissues [26]. HSP60 expression was sig-
nificantly increased in both early and advanced prostate
cancer compared with nonneoplastic prostatic epithe-
lium[27]. The upregulation of HSP60 in leukemia was
associated with major adverse prognostic factors in acute
myeloid leukemia [28]. The upregulation of HSP60 in
these cancerous tissue may be functionally correlated to
tumor initiation and progression. In viro, the survival-
promoting effects of HSP60 in vitro has also been
reported. HSP60 was detected in exosomes purified from
culture media of H292, A549 and K562 tumor cell lines,
while not in the non tumor 16HBE cells, suggesting the
spontaneous release of this molecule usually occurs in
tumor cells[29]. HSP60 could mediate the nuclear factor
kB (NF-Kb) dependent survival signaling in the cells[30].
Acute ablation of HSP60 in tumor cells results in loss of
the mitochondrial pool of survivin and activation of p53-
dependent apoptosis [31]. Cytosolic HSP60 is associated
with procaspase-3 in the apoptosis systems, including
HCT116 cells stimulated with Fas cross-linking antibody,
LNCaP cell treated with doxorubicin (Dox), or PC3 cells
treated with staurosporine (STS). Knockdown of HSP60
enhances caspase activation and cell death, suggesting the
antiapoptotic role of HSP60/procaspase-3[32]. Upon oxi-
Figure 3 Downregulation of HSP60 protein expression in 
PcDNA3.1(IGFBP7)-RKO transfectants. A: Whole cell lysates of the 
stable PcDNA3.1(IGFBP7)-RKO transfectants and PcDNA3.1-RKO trans-
fectants were prepared, and equal amounts of protein (50 μg/lane) 
were loaded. HSP60 expression was assessed using a rabbit anti-HSP60 
antibody. GAPDH is used as an internal loading control. Shown is rep-
resentive of experiments performed on at least three different isola-
tions. The amount of HSP60 protein expression in PcDNA3.1(IGFBP7)-
RKO transfectants was lower than that of the control group. B: HSP60 
concentration in cell supernatants was measured using the HSP60 ELI-
SA kit according to the manufactures instructions. Experiments were 
performed in triplicates. Results represent the mean HSP60 concentra-
tion (ng/ml) ± SD,. *, p < 0:05 vs. control.Ruan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:41
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dative stress, the antiapoptotic Hsp60/procaspase-3 com-
plex persists in mucoepidermoid carcinoma cells[33].
However, the role of HSP60 is context based. There is
some data in contrast. Downregulation of HSP60 was
found in prostate cancer[34]and lung cancer[35]. Positive
HSP60 expression in esophageal squamous cell carci-
noma[36], ovarian cancer [37] and bladder cancer[38]
correlated with good prognosis for the patients. Mecha-
nistic studies in different cell models indicated that asso-
ciation of HSP60 with procaspase-3 promotes caspase-3
maturation and activation, suggesting a pro-apoptotic
role[32,39,40].
In the past decades, regarding HSP60's roles in CRC,
most of the data come from expression observations. As
shown by immunohistochemistry, western blot[41-43]
and by cDNA microarray analysis[44,45], it was found
that HSP60 was overexpressed in CRC tissue. The levels
of HSP60 correlated with tumor grade and stage and with
occurrence of lymph node metastases[44]. While the data
on the exact biological function of HSP60 in CRC cells is
still lack. In this study, to clarify the biological role of the
down-regulation of HSP60 induced by IGFBP7, we also
explored the function of HSP60 protein in
PcDNA3.1(IGFBP7)RKO cells. We found that addition of
recombinant HSP60 could increase the proliferation rate
and increase the colony formation ability of
PcDNA3.1(IGFBP7)-RKO cells. The studies provide the
evidence that 1. HSP60 protein may be a key molecule
enrolled in CRC initiation and progression. 2. Downregu-
lation of HSP60 may participate in, at least in part, the
growth inhibiting role of IGFBP7 on colon cancer cells.
However, the exact underlying molecular mechanism is
still unclear. Both IGFBP7 and HSP60 could influence the
extracellular signal pathways. Wajapeyee et al. reported
that secretion of IGFBP7 acted through autocrine/para-
crine pathways to inhibit mitogen-activated protein
kinase (MAPK)- extracellular signal -regulated kinase
(ERK) signaling [46]. Zhang et al. reported that HSP60
protected epithelial cells from stress-induced death
through activation of ERK and inhibition of caspase 3
[47]. Whether HSP60 is complexed with pro-caspase 3
and influenced the caspase 3 and ERK signaling in colon
cancer cells will remain an active subject of our ongoing
research.
Conclusion
We have identified six candidate proteins whose expres-
sion were downregulated by reintroduction of IGFBP7 in
the colon cancer RKO cells using a proteomics approach.
These results contributed to our better understanding of
Figure 4 HSP60 protein decreased the proliferation rate and colony formation ability of PcDNA3.1(IGFBP7)-RKO cells. A: PcDNA3.1(IGFBP7)-
RKO cells were plated in sextuple in 96-well microtitre plates at 3 × 103/well, cultured with medium with or without recombinant HSP60(1 μg/ml). Ten 
μl of CCK8 was added to each well at the indicated time (12 h, 24 h, 36 h, 48 h, 60 h, 72 h). Cellular viability was determined by measuring the absor-
bance of the converted dye at 450 nm two hours after adding CCK8. Values shown are mean ± SD for sextuple cultures from one experiment, repre-
sentive of three independent experiments conducted. B: PcDNA3.1(IGFBP7)-RKO cells (500/well) were seeded into 0.3% Bacto-agar over a 0.6% agar 
bottom layer in triplicate in 6-well plates, with or without 1 μg/ml HSP60. After 3 weeks of incubation, colony number (>100 μm)were analyzed. Values 
are mean ± S.D for data from three independent experiments. C: Colony size was also analyzed under microscopy. Representive size of the colony was 
photographed under high power microscopy (×100).Ruan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:41
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the potential underlying molecular mechanism for
IGFBP7's tumor suppressive role in CRC. Downregula-
tion of HSP60 may be responsible for, at least in part, the
proliferation inhibiting role of IGFBP7 in colorectal can-
cer cells. Further studies are warranted to elaborate the
exact biological role and the molecular mechanism for
HSP60 in colorectal carcinogenesis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RWJ carried out the design of the study, performed the cell growth assay, soft
agar colony formation assay, western blot and ELISA assay, drafted the manu-
script and participated in the proteomics study. WYH performed the two-
dimensional gel electrophoresis, participated in mass spectrometry identifica-
tion assay. MY participated in the cell culture, protein extraction and two-
dimensional gel electrophoresis assay. XXM participated in the two-dimen-
sional gel electrophoresis study. LJ participated in the mass spectrometry iden-
tification assay. CJ participated in the cell culture and ELISA assay. LMD
participated in the design of the study, carried out the statistical analysis and
helped drafting the manuscript. All authors read and approved the final manu-
script.
Acknowledgements
We thank the Research Center for Proteome Analysis, the Institute of Biochem-
istry and Cell Biology, the Shanghai Institute for Biological Science, and the Chi-
nese Academy of Sciences for helping in MS analysis. This work was supported 
by grants from China National "973" program (2007CB914304), the National 
Scientific Foundation of China (30570840, 30770989, 30900236) and the Zheji-
ang Provincial Natural Science Foundation of China (D2080011).
Author Details
1Department of Pathology, School of Medicine, Zhejiang University, 388 
Yuhangtang Road, Hangzhou 310058, Zhejiang Province, China and 
2Department of Respiratory Diseases, Sir Run Run Shaw Hospital, Zhejiang 
University, 3 East Qingchun Road, Hangzhou 310016, China
References
1. Luo MJ, Lai MD: Identification of differentially expressed genes in 
normal mucosa, adenoma and adenocarcinoma of colon by SSH.  
World J Gastroenterol 2001, 7:726-31.
2. Murphy M, Pykett MJ, Harnish P, Zang KD, George DL: Identification and 
characterization of genes differentially expressed in meningiomas.  Cell 
Growth Differ 1993, 4:715-22.
3. Baxter RC, Binoux MA, Clemmons DR, Conover CA, Drop SL, Holly JM, 
Mohan S, Oh Y, Rosenfeld RG: Recommendations for nomenclature of 
the insulin-like growth factor binding protein superfamily.  
Endocrinology 1998, 139:4036.
4. Swisshelm K, Ryan K, Tsuchiya K, Sager R: Enhanced expression of an 
insulin growth factor-like binding protein (mac25) in senescent human 
mammary epithelial cells and induced expression with retinoic acid.  
Proc Natl Acad Sci USA 1995, 92:4472-6.
5. Akaogi K, Okabe Y, Sato J, Nagashima Y, Yasumitsu H, Sugahara K, Miyazaki 
K: Specific accumulation of tumor-derived adhesion factor in tumor 
blood vessels and in capillary tube-like structures of cultured vascular 
endothelial cells.  Proc Natl Acad Sci USA 1996, 93:8384-9.
6. Yamauchi T, Umeda F, Masakado M, Isaji M, Mizushima S, Nawata H: 
Purification and molecular cloning of prostacyclin-stimulating factor 
from serum-free conditioned medium of human diploid fibroblast 
cells.  Biochem J 1994, 303(Pt2):591-8.
7. Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q, Lv B, Hu H, Lin J, Cui J, Di M, 
Dong J, Lai M: IGFBP7 Plays a Potential Tumor Suppressor Role in 
Colorectal Carcinogenesis.  Cancer Biol Ther 2007, 6:.
8. Ma Y, Lu B, Ruan W, Wang H, Lin J, Hu H, Deng H, Huang Q, Lai M: Tumor 
suppressor gene insulin-like growth factor binding protein-related 
protein 1 (IGFBP-rP1) induces senescence-like growth arrest in 
colorectal cancer cells.  Exp Mol Pathol 2008, 85:141-5.
9. Xu F, Wang F, Di M, Huang Q, Wang M, Hu H, Jin Y, Dong J, Lai M: 
Classification based on the combination of molecular and pathologic 
predictors is superior to molecular classification on prognosis in 
colorectal carcinoma.  Clin Cancer Res 2007, 13:5082-8.
10. Kato MV: A secreted tumor-suppressor, mac25, with activin-binding 
activity.  Mol Med 2000, 6:126-35.
11. Kato MV, Sato H, Tsukada T, Ikawa Y, Aizawa S, Nagayoshi M: A follistatin-
like gene, mac25, may act as a growth suppressor of osteosarcoma 
cells.  Oncogene 1996, 12:1361-4.
12. Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR: Insulin-like 
growth factor binding protein-related protein 1 (IGFBP-rP1) is a 
potential tumor suppressor protein for prostate cancer.  Cancer Res 
1999, 59:2370-5.
13. Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR: Over-expression of 
insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/
mac25) in the M12 prostate cancer cell line alters tumor growth by a 
delay in G1 and cyclin A associated apoptosis.  Oncogene 2002, 
21:140-7.
14. Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K: Insulin-like 
growth factor binding protein-related protein 1 inhibits proliferation of 
MCF-7 breast cancer cells via a senescence-like mechanism.  Cell 
Growth Differ 2002, 13:205-13.
15. Xing X, Lai M, Gartner W, Xu E, Huang Q, Li H, Chen G: Identification of 
differentially expressed proteins in colorectal cancer by proteomics: 
down-regulation of secretagogin.  Proteomics 2006, 6:2916-23.
16. Wang Y, Ma Y, Lu B, Xu E, Huang Q, Lai M: Differential expression of 
mimecan and thioredoxin domain-containing protein 5 in colorectal 
adenoma and cancer: a proteomic study.  Exp Biol Med (Maywood) 2007, 
232:1152-9.
17. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein 
identification by searching sequence databases using mass 
spectrometry data.  Electrophoresis 1999, 20:3551-67.
18. Sagynaliev E, Steinert R, Nestler G, Lippert H, Knoch M, Reymond MA: 
Web-based data warehouse on gene expression in human colorectal 
cancer.  Proteomics 2005, 5:3066-78.
19. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D: Protein expression profiles 
in pancreatic adenocarcinoma compared with normal pancreatic 
tissue and tissue affected by pancreatitis as detected by two-
dimensional gel electrophoresis and mass spectrometry.  Cancer Res 
2004, 64:9018-26.
20. Greenbaum D, Luscombe NM, Jansen R, Qian J, Gerstein M: Interrelating 
different types of genomic data, from proteome to secretome: 'oming 
in on function.  Genome Res 2001, 11:1463-8.
21. Bukau B, Horwich AL: The Hsp70 and Hsp60 chaperone machines.  Cell 
1998, 92:351-66.
22. Macario AJ, De Macario EC: Chaperonopathies by defect, excess, or 
mistake.  Ann N Y Acad Sci 2007, 1113:178-91.
23. Cappello F, Macario Conway de E, Di Felice V, Zummo G, Macario AJ: 
Chlamydia trachomatis infection and anti-Hsp60 immunity: the two 
sides of the coin.  PLoS Pathog 2009, 5:e1000552.
24. Cappello F, de Macario CE, Marasa L, Zummo G, Macario AJ: Hsp60 
expression, new locations, functions and perspectives for cancer 
diagnosis and therapy.  Cancer Biol Ther 2008, 7:801-9.
25. Castle PE, Ashfaq R, Ansari F, Muller CY: Immunohistochemical 
evaluation of heat shock proteins in normal and preinvasive lesions of 
the cervix.  Cancer Lett 2005, 229:245-52.
26. Desmetz C, Bibeau F, Boissiere F, Bellet V, Rouanet P, Maudelonde T, 
Mange A, Solassol J: Proteomics-based identification of HSP60 as a 
tumor-associated antigen in early stage breast cancer and ductal 
carcinoma in situ.  J Proteome Res 2008, 7:3830-7.
27. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, 
Fordham M, Neoptolemos JP, Ke Y, Foster> SC: Heat shock protein 
expression independently predicts clinical outcome in prostate cancer.  
Cancer Res 2000, 60:7099-105.
28. Thomas X, Campos L, Mounier C, Cornillon J, Flandrin P, Le QH, Piselli S, 
Guyotat D: Expression of heat-shock proteins is associated with major 
adverse prognostic factors in acute myeloid leukemia.  Leuk Res 2005, 
29:1049-58.
Received: 7 February 2010 Accepted: 30 April 2010 
Published: 30 April 2010
This article is available from: http://www.jeccr.com/content/29/1/41 © 2010 Ruan et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Experimental & Clinical Cancer Research 2010, 29:41Ruan et al. Journal of Experimental & Clinical Cancer Research 2010, 29:41
http://www.jeccr.com/content/29/1/41
Page 9 of 9
29. Merendino AM, Bucchieri F, Campanella C, Marciano V, Ribbene A, David 
S, Zummo G, Burgio G, Corona FD, de Macario EC, Macario AJ, Cappello F: 
Hsp60 is actively secreted by human tumor cells.  PLoS One 5:e9247.
30. Chun JN, Choi B, Lee KW, Lee DJ, Kang DH, Lee JY, Song IS, Kim HI, Lee SH, 
Kim HS, Lee NK, Lee SY, Lee KJ, Kim J, Kang SW: Cytosolic Hsp60 is 
involved in the NF-kappaB-dependent survival of cancer cells via IKK 
regulation.  PLoS One 5:e9422.
31. Ghosh JC, Dohi T, Kang BH, Altieri DC: Hsp60 regulation of tumor cell 
apoptosis.  J Biol Chem 2008, 283:5188-94.
32. Chandra D, Choy G, Tang DG: Cytosolic accumulation of HSP60 during 
apoptosis with or without apparent mitochondrial release: evidence 
that its pro-apoptotic or pro-survival functions involve differential 
interactions with caspase-3.  J Biol Chem 2007, 282:31289-301.
33. Campanella C, Bucchieri F, Ardizzone NM, Gammazza Marino A, 
Montalbano A, Ribbene A, Di Felice V, Bellafiore M, David S, Rappa F, 
Marasa M, Peri G, Farina F, Czarnecka AM, Conway de Macario E, Macario 
AJ, Zummo G, Cappello F: Upon oxidative stress, the antiapoptotic 
Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma 
cells.  Eur J Histochem 2008, 52:221-8.
34. Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH, Stevenson 
MA, Calderwood SK: Expression of heat shock proteins and heat shock 
protein messenger ribonucleic acid in human prostate carcinoma in 
vitro and in tumors in vivo.  Cell Stress Chaperones 2005, 10:46-58.
35. Cappello F, Di Stefano A, David S, Rappa F, Anzalone R, La Rocca G, D'Anna 
SE, Magno F, Donner CF, Balbi B, Zummo G: Hsp60 and Hsp10 down-
regulation predicts bronchial epithelial carcinogenesis in smokers with 
chronic obstructive pulmonary disease.  Cancer 2006, 107:2417-24.
36. Faried A, Sohda M, Nakajima M, Miyazaki T, Kato H, Kuwano H: Expression 
of heat-shock protein Hsp60 correlated with the apoptotic index and 
patient prognosis in human oesophageal squamous cell carcinoma.  
Eur J Cancer 2004, 40:2804-11.
37. Schneider J, Jimenez E, Marenbach K, Romero H, Marx D, Meden H: 
Immunohistochemical detection of HSP60-expression in human 
ovarian cancer. Correlation with survival in a series of 247 patients.  
Anticancer Res 1999, 19:2141-6.
38. Lebret T, Watson RW, Molinie V, O'Neill A, Gabriel C, Fitzpatrick JM, Botto H: 
Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in 
bladder carcinoma.  Cancer 2003, 98:970-7.
39. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S: Presence of a pre-
apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the 
mitochondrial fraction of jurkat cells.  Embo J 1999, 18:2040-8.
40. Xanthoudakis S, Roy S, Rasper D, Hennessey T, Aubin Y, Cassady R, Tawa P, 
Ruel R, Rosen A, Nicholson DW: Hsp60 accelerates the maturation of 
pro-caspase-3 by upstream activator proteases during apoptosis.  
Embo J 1999, 18:2049-56.
41. Zhang WL, Gao XQ, Han JX, Wang GQ, Yue LT: [Expressions of heat shock 
protein (HSP) family HSP 60, 70 and 90alpha in colorectal cancer 
tissues and their correlations to pathohistological characteristics.].  Ai 
Zheng 2009, 28:612-618.
42. Cappello F, Bellafiore M, Palma A, David S, Marciano V, Bartolotta T, Sciume 
C, Modica G, Farina F, Zummo G, Bucchieri F: 60KDa chaperonin (HSP60) 
is over-expressed during colorectal carcinogenesis.  Eur J Histochem 
2003, 47:105-10.
43. Cappello F, David S, Rappa F, Bucchieri F, Marasa L, Bartolotta TE, Farina F, 
Zummo G: The expression of HSP60 and HSP10 in large bowel 
carcinomas with lymph node metastase.  BMC Cancer 2005, 5:139.
44. Mori D, Nakafusa Y, Miyazaki K, Tokunaga O: Differential expression of 
Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat 
shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in 
human colorectal cancer progression using human cancer cDNA 
microarrays.  Pathol Res Pract 2005, 201:777-89.
45. Spisak S, Galamb B, Wichmann B, Sipos F, Galamb O, Solymosi N, Nemes B, 
Tulassay Z, Molnar B: [Tissue microarray (TMA) validated progression 
markers in colorectal cancer using antibody microarrays].  Orv Hetil 
2009, 150:1607-13.
46. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR: Oncogenic 
BRAF induces senescence and apoptosis through pathways mediated 
by the secreted protein IGFBP7.  Cell 2008, 132:363-74.
47. Zhang L, Pelech S, Uitto VJ: Bacterial GroEL-like heat shock protein 60 
protects epithelial cells from stress-induced death through activation 
of ERK and inhibition of caspase 3.  Exp Cell Res 2004, 292:231-40.
doi: 10.1186/1756-9966-29-41
Cite this article as: Ruan et al., HSP60, a protein downregulated by IGFBP7 in 
colorectal carcinoma Journal of Experimental & Clinical Cancer Research 2010, 
29:41